Cinchonine

Cinchonine is a naturally occurring cinchona alkaloid derived from the bark of Cinchona trees, structurally related to quinine but lacking its methoxy group. It inhibits heme polymerization in Plasmodium parasites and modulates P-glycoprotein activity, making it a subject of pharmacological rather than dietary supplement research.

Origin & History

Cinchonine is a naturally occurring alkaloid found in the bark of Cinchona species, particularly Cinchona micrantha, native to South America. It is extracted through isolation processes from cinchona bark and appears as white or faintly yellow crystalline powder with the molecular formula C₁₉H₂₂N₂O.

Historical & Cultural Context

Cinchonine occurs in cinchona bark, historically used in traditional Andean and later European medicine for malaria treatment due to related alkaloids like quinine. Its isolation and structure were elucidated by Rabe in the early 20th century, building on cinchona's importation by Jesuits from the 1600s.

Health Benefits

• No clinically proven health benefits - no human clinical trials identified in available research
• Historically associated with cinchona bark's antimalarial properties, though specific benefits of isolated cinchonine not established
• Used primarily in chemical synthesis rather than as a therapeutic agent
• Light-sensitive compound requiring special storage conditions
• No evidence-based therapeutic applications documented

How It Works

Cinchonine inhibits the formation of hemozoin (malaria pigment) by interfering with heme polymerization in Plasmodium falciparum, preventing the parasite from detoxifying toxic free heme. It also acts as a potent inhibitor of P-glycoprotein (P-gp, ABCB1), a membrane efflux transporter, which has raised interest in reversing multidrug resistance in cancer cells. Additionally, cinchonine has demonstrated inhibition of cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4, affecting metabolism of multiple co-administered drugs.

Scientific Research

No key human clinical trials, RCTs, or meta-analyses were identified for cinchonine as a primary therapeutic agent. The available sources note its occurrence in cinchona bark alongside quinine but do not reference specific clinical studies or PubMed PMIDs for cinchonine itself.

Clinical Summary

No human clinical trials have specifically evaluated isolated cinchonine as a therapeutic agent or dietary supplement, leaving its clinical evidence base essentially nonexistent. Historical use of cinchona bark preparations — which contain cinchonine alongside quinine, quinidine, and cinchonidine — provided empirical support for antimalarial activity, but attributing outcomes to cinchonine alone is not possible from this data. In vitro studies demonstrate measurable P-glycoprotein inhibition and antiparasitic activity at micromolar concentrations, but these findings have not been translated into controlled human trials. The overall evidence strength is preclinical only, and cinchonine cannot be recommended for any therapeutic indication based on current research.

Nutritional Profile

Cinchonine (C19H22N2O, molecular weight 294.39 g/mol) is a pure alkaloid compound and not a nutritional substance. It contains no macronutrients (zero protein, fat, or carbohydrates in functional dietary sense), no dietary fiber, no vitamins, and no essential minerals. As a stereoisomeric cinchona alkaloid, its bioactive components are confined to a quinoline ring system and a quinuclidine ring with a vinyl group and a secondary alcohol (hydroxyl group at C-9 position). It is structurally similar to quinine but lacks the methoxy group at C-6'. Naturally occurring in cinchona bark (Cinchona officinalis) at concentrations typically ranging from 0.2–0.5% of dry bark weight, alongside quinine, quinidine, and cinchonidine. As an isolated compound used in chemical synthesis and as a chiral catalyst, it has no caloric value or nutritional contribution. Its bioavailability as a pharmaceutical-relevant compound is characterized by oral absorption, though human pharmacokinetic data for isolated cinchonine is extremely limited compared to quinine. The compound is light-sensitive and degrades upon UV exposure, which would further reduce any theoretical bioactive fraction. No dietary reference values, recommended intakes, or nutritional benchmarks exist for this compound.

Preparation & Dosage

No clinically studied dosage ranges or standardization details are available, as no human clinical data has been reported. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

None established - no synergistic ingredients identified in research

Safety & Interactions

Cinchonine shares structural and pharmacological similarities with quinine and quinidine, raising concern for cinchonism — a syndrome involving tinnitus, headache, nausea, and visual disturbances at elevated doses. Its inhibition of CYP2D6 and CYP3A4 creates significant potential for drug-drug interactions, particularly with anticoagulants, antiarrhythmics, and drugs with narrow therapeutic windows. Cinchona alkaloids as a class are contraindicated in pregnancy due to documented uterine stimulant effects and potential teratogenicity observed in animal models. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency face heightened risk of hemolytic anemia from cinchona-derived alkaloids.